AllianceBernstein
CCCC icon

AllianceBernstein’s C4 Therapeutics CCCC Stock Holding History

AllianceBernstein’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,800
Closed -$76.5K – 3248
2025
Q1 		$76.5K Hold
47,800
– – ﹤0.01% 3092
2024
Q4 		$172K Hold
47,800
– – ﹤0.01% 3051
2024
Q3 		$272K Buy
47,800
+2,020
+4% +$12.2K ﹤0.01% 2955
2024
Q2 		$212K Buy
+45,780
New +$273K ﹤0.01% 3014
2023
Q2 		– Sell
-52,000
Closed -$163K – 3181
2023
Q1 		$163K Hold
52,000
– – ﹤0.01% 2956
2022
Q4 		$307K Buy
52,000
+4,300
+9% +$35.7K ﹤0.01% 2860
2022
Q3 		$418K Sell
47,700
-3,100
-6% -$32.2K ﹤0.01% 2729
2022
Q2 		$383K Sell
50,800
-93,921
-65% -$826K ﹤0.01% 2794
2022
Q1 		$3.51M Buy
144,721
+42,154
+41% +$1.02M ﹤0.01% 1759
2021
Q4 		$3.3M Buy
102,567
+21,370
+26% +$845K ﹤0.01% 1843
2021
Q3 		$3.63M Buy
81,197
+19,915
+32% +$853K ﹤0.01% 1781
2021
Q2 		$2.32M Buy
+61,282
New +$2.19M ﹤0.01% 2110

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's CCCC Position: Q2 2025 in Review

AllianceBernstein sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 47,800 shares — an estimated $76.5K sold.

AllianceBernstein first reported a position in CCCC in Q2 2021 and held it in 12 quarters. The position peaked at $3.63M in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • AllianceBernstein reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 47,800 C4 Therapeutics shares in Q2 2025, an estimated $76.5K.
  • AllianceBernstein first reported a position in C4 Therapeutics in Q2 2021 and held it in 12 quarters.
  • AllianceBernstein's C4 Therapeutics position peaked at $3.63M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.